PT2001891E - Derivados de bruprenorfina e utilizações destes - Google Patents

Derivados de bruprenorfina e utilizações destes Download PDF

Info

Publication number
PT2001891E
PT2001891E PT77321776T PT07732177T PT2001891E PT 2001891 E PT2001891 E PT 2001891E PT 77321776 T PT77321776 T PT 77321776T PT 07732177 T PT07732177 T PT 07732177T PT 2001891 E PT2001891 E PT 2001891E
Authority
PT
Portugal
Prior art keywords
buprenorphine
buprenorphine derivatives
enhanced
derivatives
moderate
Prior art date
Application number
PT77321776T
Other languages
English (en)
Inventor
Chapleo Christopher Bourne
John William Lewis
Original Assignee
Rb Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rb Pharmaceuticals Ltd filed Critical Rb Pharmaceuticals Ltd
Publication of PT2001891E publication Critical patent/PT2001891E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/09—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems
    • C07D489/10—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems with a bridge between positions 6 and 14
    • C07D489/12—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems with a bridge between positions 6 and 14 the bridge containing only two carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT77321776T 2006-03-28 2007-03-27 Derivados de bruprenorfina e utilizações destes PT2001891E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0606124.6A GB0606124D0 (en) 2006-03-28 2006-03-28 Buprenorphine derivatives and uses thereof

Publications (1)

Publication Number Publication Date
PT2001891E true PT2001891E (pt) 2013-10-30

Family

ID=36384277

Family Applications (1)

Application Number Title Priority Date Filing Date
PT77321776T PT2001891E (pt) 2006-03-28 2007-03-27 Derivados de bruprenorfina e utilizações destes

Country Status (21)

Country Link
US (1) US7964610B2 (pt)
EP (1) EP2001891B1 (pt)
JP (1) JP5167446B2 (pt)
KR (1) KR101430626B1 (pt)
CN (2) CN104151320A (pt)
AU (1) AU2007231133B2 (pt)
BR (1) BRPI0709157A8 (pt)
CA (1) CA2647417C (pt)
DK (1) DK2001891T3 (pt)
ES (1) ES2432169T3 (pt)
GB (1) GB0606124D0 (pt)
IL (1) IL193917A (pt)
MX (1) MX2008011984A (pt)
MY (1) MY151025A (pt)
NZ (1) NZ570997A (pt)
PL (1) PL2001891T3 (pt)
PT (1) PT2001891E (pt)
RU (1) RU2435773C2 (pt)
TW (1) TWI501969B (pt)
WO (1) WO2007110636A1 (pt)
ZA (1) ZA200807614B (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2064215B1 (en) * 2006-09-22 2015-07-15 Zynerba Pharmaceuticals, Inc. Transdermally deliverable buprenorphine prodrugs and abuse-resistant compositions thereof
DK2307420T3 (da) * 2008-04-24 2012-02-27 Janssen Pharmaceutica Nv Nalmefendiester-prodrugs
FR2975912B1 (fr) 2011-05-30 2013-06-14 Flamel Tech Sa Composition a liberation controlee de buprenorphine
US20180305370A1 (en) * 2015-10-26 2018-10-25 Orphomed, Inc. Ethylene glycol ether of buprenorphine
JP2019507783A (ja) 2016-03-09 2019-03-22 エムダブリュ エンキャップ リミテッド 乱用防止医薬製剤
SI3512518T1 (sl) 2016-09-13 2023-04-28 Alar Pharmaceuticals Inc. Formulacije buprenorfina z zadržanim sproščanjem
WO2019064026A1 (en) 2017-09-29 2019-04-04 Orexo Ab NEW PHARMACEUTICAL COMPOSITIONS
TWI838372B (zh) * 2018-05-11 2024-04-11 昱展新藥生技股份有限公司 丁基原啡因衍生物之長效注射劑型及結晶型
GB201904767D0 (en) 2019-04-04 2019-05-22 Orexo Ab New pharmaceutical compositions
WO2023102489A1 (en) * 2021-12-03 2023-06-08 Board Of Regents Of The University Of Nebraska Compounds, nanoparticles, and pharmaceutical compositions for the treatment of drug addiction
CN116283893B (zh) * 2023-03-22 2024-04-26 阜阳欣奕华制药科技有限公司 硫代羟基乙酸酐的制备方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4668685A (en) 1984-07-05 1987-05-26 E.I. Du Pont De Nemours And Company Substituted benzoate ester prodrug derivatives of 3-hydroxymorphinans, which are analgesics or narcotic antagonists
GB8728294D0 (en) 1987-12-03 1988-01-06 Reckitt & Colmann Prod Ltd Treatment compositions
US5985880A (en) 1996-06-05 1999-11-16 Delta Pharmaceuticals Compositions and methods for reducing respiratory depression and attendant side effects of mu opioid compounds
US5512593A (en) 1993-03-02 1996-04-30 John S. Nagle Composition and method of treating depression using natoxone or naltrexone in combination with a serotonin reuptake inhibitor
US5750534A (en) 1994-03-16 1998-05-12 National Science Council Nalbuphine esters having long acting analgesic action and method of use
US6004969A (en) 1996-04-15 1999-12-21 National Science Council Transdermal delivery of buprenorphine preparations
KR100204659B1 (ko) 1996-05-28 1999-06-15 강재헌 신규한 부프레노핀계 진통제용 화합물
US6225321B1 (en) 1997-06-05 2001-05-01 Oliver Yoa-Pu Hu Long analgesic acting nalbuphine polyester derivative and method of use
NZ511527A (en) 1998-11-13 2002-10-25 Jago Res A Dry powder for inhalation
GEP20053614B (en) 2000-02-08 2005-09-26 Euro Celtique Sa Compositions for Oral Administration Containing Opioid Agonist
US6716449B2 (en) 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
JP2005523876A (ja) 2001-09-26 2005-08-11 ペンウェスト ファーマシューティカルズ カンパニー 乱用の可能性が低減したオピオイド製剤
US20040033253A1 (en) 2002-02-19 2004-02-19 Ihor Shevchuk Acyl opioid antagonists
US7666876B2 (en) 2002-03-19 2010-02-23 Vernalis (R&D) Limited Buprenorphine formulations for intranasal delivery
US7776314B2 (en) 2002-06-17 2010-08-17 Grunenthal Gmbh Abuse-proofed dosage system
US20050186139A1 (en) 2002-10-25 2005-08-25 Gruenenthal Gmbh Abuse-proofed dosage form
US20050191244A1 (en) 2002-10-25 2005-09-01 Gruenenthal Gmbh Abuse-resistant pharmaceutical dosage form
DE10250084A1 (de) 2002-10-25 2004-05-06 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
DE10250087A1 (de) 2002-10-25 2004-05-06 Grünenthal GmbH Gegen Missbrauch gesicherte Darreichungsform
US7084150B2 (en) * 2002-10-25 2006-08-01 Euro-Celtique S.A. Analogs and prodrugs of buprenorphine
CN1263760C (zh) * 2002-11-12 2006-07-12 财团法人奇美医院 新颖的丁丙诺啡酯衍生物及其制备方法，以及长效作用镇痛药学组合物
DE60224288T2 (de) * 2002-11-25 2009-04-16 Chi Mei Foundation Medical Center Buprenorphinesterderivate, Verfahren zu ihrer Herstellung, und langwirksame analgetische Arzneimittel
JP2004175706A (ja) * 2002-11-26 2004-06-24 Chi Mei Foundation Medical Center 新規なブプレノルフィンのエステル誘導体及びそれらの調製方法、及び長時間効力持続性鎮痛薬剤組成物
TW200500067A (en) * 2003-01-21 2005-01-01 Control Delivery Sys Inc Salts of codrugs and uses related thereto
CA2515146C (en) 2003-02-04 2011-12-06 Chrysalis Technologies Incorporated Aerosol formulations and aerosol delivery of buspirone, buprenorphine, triazolam, cyclobenzaprine and zolpidem
US7195882B2 (en) 2003-06-03 2007-03-27 Roche Diagnostics Operations, Inc. Monoclonal antibodies specific for buprenorphine and metabolites thereof
US7759358B2 (en) 2003-07-23 2010-07-20 Crooks Peter A Oral bioavailable prodrugs
US7589233B2 (en) 2003-07-29 2009-09-15 Signature R&D Holdings, Llc L-Threonine derivatives of high therapeutic index
US7220842B2 (en) 2004-04-05 2007-05-22 Dade Behring Inc. Immunoassays for buprenorphine and norbuprenorphine

Also Published As

Publication number Publication date
RU2435773C2 (ru) 2011-12-10
US7964610B2 (en) 2011-06-21
CN104151320A (zh) 2014-11-19
TW200806672A (en) 2008-02-01
JP5167446B2 (ja) 2013-03-21
EP2001891A1 (en) 2008-12-17
RU2008142527A (ru) 2010-05-10
IL193917A (en) 2014-12-31
AU2007231133A2 (en) 2008-10-16
JP2009531406A (ja) 2009-09-03
PL2001891T3 (pl) 2014-03-31
ZA200807614B (en) 2009-10-28
BRPI0709157A2 (pt) 2011-06-28
GB0606124D0 (en) 2006-05-03
BRPI0709157A8 (pt) 2018-04-24
DK2001891T3 (da) 2013-11-04
AU2007231133B2 (en) 2011-09-01
US20100234412A1 (en) 2010-09-16
AU2007231133A8 (en) 2011-08-25
KR101430626B1 (ko) 2014-08-18
KR20080105124A (ko) 2008-12-03
MX2008011984A (es) 2008-10-03
ES2432169T3 (es) 2013-12-02
CN101410402A (zh) 2009-04-15
CA2647417C (en) 2014-09-23
TWI501969B (zh) 2015-10-01
EP2001891B1 (en) 2013-07-24
MY151025A (en) 2014-03-31
NZ570997A (en) 2011-08-26
CA2647417A1 (en) 2007-10-04
AU2007231133A1 (en) 2007-10-04
WO2007110636A1 (en) 2007-10-04

Similar Documents

Publication Publication Date Title
PT2001891E (pt) Derivados de bruprenorfina e utilizações destes
WO2007115305A3 (en) Oral dosage forms including an antiplatelet agent and an acid inhibitor
WO2009079451A3 (en) Compositions and methods of promoting wound healing
HK1114350A1 (en) An extract for preventing or treating thrombotic diseases
WO2007081751A9 (en) Compositions and methods for the treatment of cancer
MX2008011633A (es) Aminoquinolonas como inhibidores de gsk-3.
PL1998730T3 (pl) Nowy system uciskowy do leczenia i zapobiegania patologiom pochodzenia żylnego
EP2049151A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF CANCER
MX2011006254A (es) Composiciones aclaradoras de la piel con inhibidores de acetilcolinesterasa.
WO2007084753A3 (en) Skin cleansing article
WO2007120485A3 (en) Methods of treating pain with alkylxanthines and antiepileptics and compositions for use therefor
NZ571858A (en) Methods of treating, reducing and inhibiting the appearance of ageing in the skin
EP2043859A4 (en) STYRESTED TERPEN RESINS AND METHOD FOR THE PRODUCTION AND USE THEREOF
WO2007127163A3 (en) Cns-tumor treatment method and composition
MX2009004142A (es) Metodo para prevenir o tratar sindrome metabolico.
WO2011011706A3 (en) Methods and compositions for treating or preventing autoimmune diseases using immunomodulatory agents
MX343222B (es) Combinacion de teobrina con un descongestionante y su uso para el tratamiento de la tos.
UA105940C2 (uk) Лікарська комбінація з теоброміном та опіатом і її використання в лікуванні кашлю
MX2009005640A (es) Metodos para el tratamiento del abuso, adiccion y dependencia del alcohol.
AU2010298020A8 (en) Combination
WO2008063853A3 (en) Cancer treatment method
AP2011005746A0 (en) Method for stimulating biodegradation and the degassing of waste disposal sites.
WO2008073381A3 (en) Synergistic effects of combinations of nornicotine and opioids for the treatment of pain
WO2008033368A3 (en) Boroproline compound and cytokine combination therapy
WO2006053322A3 (en) Compositions and methods for inferring an adverse effect in response to a drug treatment